Powerful full-field clearance and
reduction of total lesion count1,2

Intense local skin reactions including skin weeping or erosion can occur after a few applications of ZYCLARA Cream and may require an interruption of dosing

Provides significant complete clearance of AK lesions

Complete clearance included both those lesions present at baseline and those that were revealed during treatment; it was defined as the absence of clinically visible or palpable AK lesions in the treatment area. In 2 double-blind, randomized, placebo-controlled clinical studies, 479 subjects were treated with ZYCLARA Cream 3.75% or 2.5% or placebo once daily for two 2-week treatment cycles separated by a 2-week, no-treatment period and followed for 8 weeks to end of study. The primary efficacy endpoint was complete clearance of AK lesions at Week 14 End of Study. 1,2

Secondary efficacy endpoints included partial clearance rate, defined as proportion of subjects at EOS with > 75% reduction in the number of AK lessons.1,3 Partial clearance of AK lesions in Studies 1 and 2 were 46% and 73% for patients on Zyclara 3.75% vs 19% and 27% for placebo patients, respectively (P < 0.001). 1,2

Flu like symptoms may accompany, or even precede, local skin reactions and may include fatigue, nausea, fever, myalgias, arthralgais, malaise, and chills

Significant reductions in total lesion count for AK patients1,2

Large treatment area – full face or balding scalp (up to 200 cm2)1

Median 9 AK lesions2

  • Study 1: 11 AK lesions at baseline for ZYCLARA 3.75% patients
  • Study 2: 9 AK lesions at baseline for ZYCLARA 3.75% patients

This secondary endpoint was the percent change from baseline to Week 14 in investigator counts of AK lesions.2

Efficacy for the full-field treatment of actinic keratosis

  • Significant complete clearance of AKs1
  • Significant reductions in total lesion count1
  • Treats both visible and previously undetected AKs2

Efficacy Video

From the publishers of Practical Dermatology, the dermtube video features commentary from thought leaders for the management of actinic keratosis.


Value Savings for your Patients

Get details

Sequential Therapy

*This offer is only valid for patients with commercial insurance. Eligible uninsured patients will pay more. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is good only in the U.S. at retail pharmacies owned and operated by Walgreen Co. (or its affiliates) or other participating independent retail pharmacies. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed or otherwise restricted. Click here for other terms and conditions that apply.

INDICATION

ZYCLARA (imiquimod) Cream 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the full face or balding scalp in immunocompetent adults.

IMPORTANT SAFETY INFORMATION FOR ZYCLARA CREAM

Please click here for Prescribing Information, including Patient Information.

References: 1. ZYCLARA Cream Package Insert.Scottsdale, AZ: Medicis, the Dermatology Company; February 2012. 2. Data on file. Valeant Pharmaceuticals International Inc. 3. Jorizzo JL, Markowitz O,Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010;9(9):1101–1108.